Our COVID Vaccine Statement and other related resources for patients and our researchers and research staff are available on the COVID-19 Updates webpage.
David Krag MD
The primary aim is to determine the relative risk of death associated with the presence of tumor cells in the bone marrow of patients with early-stage breast cancer.
The primary endpoint for analysis is overall survival (OS), where OS will be the time from entry into the study to death from any cause.
Patients with early-stage breast cancer who were to undergo breast surgery were eligible for participation.
Protocol Record Retention DatesDate Records No Longer to be Kept by US Sites: 08/13/2021Date Records No Longer to be kept by Canadian Sites: 08/13/2033
We are a leading protocol organizations within the National Clinical Trials Network and we seek to improve the lives of cancer patients by conducting practice-changing, multi-institutional clinical and translational research. Learn More
NRG Oncology Foundation, Inc, is a nonprofit, tax-exempt foundation. Donations to NRG Oncology help us conduct this important mission, and are tax-deductible to the extent permitted by law.